triumph 1 trial retatrutide TRIUMPH-1 Shows Potential for As a Treatment for Obesity Finished 18 month Triumph 1

Though peptides in general are gaining traction across a range of therapeutic frontiers, from rare diseases to neurodegenerative conditions such as Alzheimers, the rise of GLP-1s as a blockbuster therapy for chronic weight management has redefined the field of peptide manufacturing

The result: you feel fuller and more satisfied after eating

Because retatrutide is not yet licensed for clinical use in the UK, these timelines are drawn from trial data rather than real-world clinical experience

And the temptation to toss your medication bag in the back seat and forget about it for six hours is real

Distinct advantages of TDDS over other drug delivery systems include self-administration, sustained drug release, and reduced dosing frequency